Press Releases

Read and download the financial news from NFL Biosciences. To receive our announcements directly in your mailbox subscribe to our mailing list.
  • 2023
  • 2022
  • 2021

October 31, 2023

NFL BIOSCIENCES, a company committed to the fight against tobacco smoking, presents its clinical devlopment advances to help smokers quit (french only)

October 5, 2023

2023 first-half business and earnings update

September 25, 2023

Promising results of the PRECESTO clinical trial revealing a prolonged effect for NFL-101 and modification of the strategy for communicating the CESTO II study results

July 18, 2023

Patent application filed in the United States for reducing alcohol consumption with NFL-301 & preparation of a pre-IND application submission with the FDA

July 5, 2023

Co-founder shareholder further strengthens his position by exercising “BSPCE” warrants

June 29, 2023

GB Holding takes a stake in the company’s capital upon the exercise of share subscription warrants

June 28, 2023

Results of the Combined General Meeting of June 27, 2023

June 21, 2023

Approval for its patent to be granted on NFL-101 in Europe and approval of the clinical development

June 9, 2023

Shareholder documentation for the Annual General Meeting (french only)

May 9, 2023

Recruitment completed for the PRECESTO study

April 28, 2023

Availability of the 2022 Annual Report (french only)

April 25, 2023

2022 full-year business and earnings update

February 27, 2023

Changes in the governance

February 22, 2023

Inclusion of the first volunteer in the PRECESTO study

February 20, 2023

NFL Biosciences receives €1.7 million in « Avance Innovation » funding from Bpifrance

February 2, 2023

Collaboration with the CEA to study the mechanism of action of its drug candidate NFL-101

January 31, 2023

Very successful capital increase for NFL Biosciences with over €3 million raised

January 30, 2023

NFL Biosciences launches a round of fundraising for approximately 2.5 million euros

November 21, 2022

NFL Biosciences takes part in the Société Francophone de Tabacologie congress (french only)

November 8, 2022

Clinical trial approved to demonstrate the complementarity of NFL-101 with other smoking cessation treatments

November 2, 2022

New patent application associating NFL-101 with other smoking cessation treatments

October 25, 2022

2022 first-half business and earnings

October 5, 2022

NFL Biosciences partners mith Themis Medicare for the development of NFL-101 in India

June 24, 2022

Participation in the first annual H.C.Wainwright Mental Health Conference (french only)

May 25, 2022

NFL Biosciences, committed to the fight against tobacco smoking, fully supports World No Tobacco Day on May 31st (french only)

May 11, 2022

Decision to approve the issuing of its patent in South Korea

April 11, 2022

Decision to approve the issuing of its patent in China

March 28, 2022

2021 full-year business and earnings

February 2, 2022

Co-development agreement for a drug candidate to reduce alcohol consumption

December 14, 2021

Phase II/III clinical trial launched for smoking cessation

November 17, 2021

Agreement signed with Diverchim to manufacture its active ingredients

October 4, 2021

2021 first-half business and earnings

September 21, 2021

Approval for its patent to be granted in the United States

September 15, 2021

Phase II/III clinical trial for NFL-101 for smokingcessation approved in France

6 septembre 2021

Analyst coverage launched with Invest Securities

July 20, 2021

Implementation of a liquidity contract (french only)

June 30, 2021

NFL Biosciences successfully listed on Euronext Growth Paris (french only)

June 16, 2021

NFL Biosciences launches its Initial Public Offering on Euronext Growth Paris (french only)

June 2, 2021

French smoking cessation innovation approved for Phase II/III clinical trial (french only)